Dr. Dinesh Khanna

We've received very touching #sclerodermastories from patients & family. Read them all at the link below. Please consider supporting the Michigan Medicine Scleroderma Program on #GivingBlueday 11/27/18, at medicine.umich.edu/dept/intmed/di… … #medicineneedsvictors #victorsinthehouse #Rheum

Exciting data on CAR-T from @Worldsclerofnd meeting in Athens in #scleroderma. Complete B cell depletion in tissue, response in RNA pol 3 Ab, and ++large clinical response. Clinical trials starting comparing CAR-T to standard of care therapies with Novartis and BMS.

Join me and Dr Monalisa Ghosh to get an update on cell therapy in # scleroderma on Friday, December 12 - 2:00 p.m. ET. Sponosred by @scleroderma us02web.zoom.us/webinar/regist…

SLS 3 is published. acrjournals.onlinelibrary.wiley.com/doi/10.1002/ac…
1. Upfront MMF+PFD vs. MMF+PLA
2. Underpowered due to Covid
3. No difference in primary end- FVC%
4. ⬆️AE and discont with MMF+PFD
What else did we learn?
A. Trends favor MMF+PFD in PROs and in HRCT QILD
B. Need well powered trials

A lot of enthusiasm about CAR-T therapy in #scleroderma. Data from Phase 1 trial sclerodermanews.com/news/car-t-cel…